Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider based in Singapore, focusing on markets in Singapore, Malaysia, and China [6] - The company aims to become a market leader in non-invasive and preventive healthcare, targeting the growing longevity sector to address the healthcare needs of over 1.8 billion people in the region [6] Acquisition Announcement - EUDA has signed a Letter of Intent (LOI) to potentially acquire Chemokine Pte Ltd, a Singapore-based biotech company [1][2] - The exclusivity period for Chemokine is set for at least 120 days, during which it cannot engage in discussions with other entities regarding similar transactions [2] Chemokine Overview - Chemokine specializes in molecular supplements and gene modulating formulations, including a next-generation immune health supplement for which EUDA has obtained exclusive worldwide distribution rights [3] - The company was founded by Professor Kah Meng Lim, a respected molecular medicine researcher with a Ph.D. from the National University of Singapore [4] Product Differentiation - Euda Helixé, the product marketed by EUDA, is designed to support energy, immune resilience, and cellular health, utilizing a unique formulation that includes molecular deer placenta, marine collagen, and bioactive antioxidants [5] - The product employs a gene activation model to modulate gene expression, activating beneficial genes while silencing harmful ones [5]